Trial reportBMC medicine2025
The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04606303 (A Single-center, Prospective, Single-arm Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-center, Prospective, Single-arm Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.
Who cites it
2 citing papers in PubMed.
- Methylated circulating tumor DNA: technical challenges and clinical applications in non-small cell lung cancer patients-a narrative review.Translational lung cancer research · 2026Review
- Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundNeoadjuvant chemoimmunotherapy does not benefit all non-small cell lung cancer (NSCLC) patients, and reliable biomarkers are urgently needed. We conducted this prospective phase II trial of neoadjuvant chemoimmunotherapy to explore the role of cell-free DNA (cfDNA) features in pathological response assessment.
methodsTotally, 100 patients with stage IIB-IIIB NSCLC were enrolled and treated with neoadjuvant toripalimab plus chemotherapy for at least 2 cycles. Targeted methylation panel sequencing and whole methylome sequencing were conducted on 195 cfDNA samples collected from 60 patients before each treatment cycle (C0, C1) and before surgery (BS), with subsequent calculations of methylation fragment ratio (MFR) and chromosome aneuploid of featured fragment (CAFF) scores, respectively. The correlations between MFR or CAFF and pathological response were evaluated.
resultsFinally, 83 patients underwent surgery, and 54 (65.1%) patients achieved major pathological response (MPR), including 38 (45.8%) with complete pathological response (pCR). The median MFR and CAFF scores in both the MPR and non-MPR groups significantly decreased after the first cycle, and the MPR group maintained low levels before surgery (P < 0.001). According to pre-defined cut-off values, the MFR and CAFF scores were recategorized as low or high status. Patients with low MFR status at BS (74.5% vs. 11.1%, P < 0.001) or low CAFF status at C1 (73.9% vs. 36.4%, P = 0.031) and BS (76.2% vs. 38.9%, P = 0.008) were more likely to achieve MPR than those with high status. Three dynamic patterns were identified: C0 low, C0 high/C1 low, and C0 high/C1 high. These patterns were further divided by BS low or high status, which indicated distinctive MPR rate (C0 low: BS low vs. high 78.9% vs 0%; C0 high/C1 low: BS low vs. high 73.9% vs. 25%; C0 high/C1 high: BS low vs. high 83.3% vs. 0%). An integrative model was constructed by incorporating immune parameters (PD-L1 and CD8 + CD28- T lymphocytes) and cfDNA features (MFR and CAFF) at C1 and BS, achieving an AUC of 0.86 (95% CI 0.80-0.92).
conclusionsDynamic monitoring of cfDNA methylation has potential to predict pathological response of neoadjuvant chemoimmunotherapy in NSCLC.
trial registrationRENAISSANCE study, NCT04606303, initiated on October 27, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.